Getting to the Root of miRNA-Mediated Gene Silencing  by Eulalio, Ana et al.
Leading Edge
EssayGetting to the Root of miRNA-Mediated 
Gene Silencing
Ana Eulalio,1 Eric Huntzinger,1 and Elisa Izaurralde1,*
1Max-Planck-Institute for Developmental Biology, Spemannstrasse 35, D-72076 Tübingen, Germany
*Correspondence: elisa.izaurralde@tuebingen.mpg.de
DOI 10.1016/j.cell.2007.12.024
MicroRNAs are ~22 nucleotide-long RNAs that silence gene expression posttranscriptionally 
by binding to the 3′ untranslated regions of target mRNAs. Although much is known about their 
biogenesis and biological functions, the mechanisms allowing miRNAs to silence gene expression 
in animal cells are still under debate. Here, we discuss current models for miRNA-mediated gene 
silencing and formulate a hypothesis to reconcile differences.MicroRNAs (miRNAs) play important 
roles in a broad range of biological pro-
cesses including development, cellular 
differentiation, proliferation, and apop-
tosis. Emerging evidence also implicates 
miRNAs in the pathogenesis of human 
diseases such as cancer and metabolic 
disorders. At least 100 miRNA genes 
have been identified in invertebrates, 
and 500–1000 in vertebrates and plants. 
Computational predictions of miRNA tar-
gets estimate that each miRNA regulates 
hundreds of different mRNAs, suggest-
ing that a large proportion of the tran-
scriptome is subject to miRNA regulation 
(reviewed by Bushati and Cohen, 2007).
To perform their regulatory func-
tions miRNAs assemble together with 
Argonaute family proteins into miRNA-
induced silencing complexes (miRISCs). 
Within these complexes, miRNAs guide 
Argonaute proteins to fully or partially 
complementary mRNA targets, which 
are then silenced posttranscriptionally 
(reviewed by Bushati and Cohen, 2007).
Despite remarkable progress in our 
understanding of miRNA biogenesis and 
function, the mechanisms used by miRNAs 
to regulate gene expression remain under 
debate. Indeed, published studies indicate 
that miRNAs repress protein expression in 
four distinct ways: (1) cotranslational pro-
tein degradation; (2) inhibition of transla-
tion elongation; (3) premature termination 
of translation (ribosome drop-off); and 
(4) inhibition of translation initiation (Fig-
ure 1). In addition, animal miRNAs can 
induce significant degradation of mRNA 
targets despite imperfect mRNA-miRNA 
base-pairing (Figure 1). MicroRNAs might also silence their targets by sequester-
ing mRNAs in discrete cytoplasmic foci 
known as mRNA processing bodies or 
P bodies, which exclude the translation 
machinery. Here, we discuss evidence 
supporting these different mechanisms of 
repression by miRNAs and the discrepan-
cies between them.
Post-initiation Mechanisms
Early studies in the worm Caenorhabditis 
elegans and recent studies in mammalian 
cell cultures present persuasive evidence 
that miRNAs repress protein synthesis 
after translation is initiated (Seggerson et 
al., 2002; Maroney et al., 2006; Nottrott et 
al., 2006; Petersen et al., 2006). Although 
these studies differ in the details, their 
conclusions stem from a common obser-
vation: in sucrose sedimentation gradients, 
miRNAs and their targets are associated 
with polysomes. These polysomes were 
shown to be actively translating mRNA 
targets because they were sensitive to a 
variety of conditions that inhibit transla-
tion. For example, they dissociate into 
monosomes or ribosomal subunits follow-
ing brief incubation with translation inhibi-
tors, such as hippuristanol, puromycin, or 
pactamycin (Maroney et al., 2006; Nottrott 
et al., 2006; Petersen et al., 2006).
The paradoxical observation that the 
targets of miRNAs appear to be actively 
translated while the corresponding protein 
product remains undetectable prompted 
the proposal that the nascent polypeptide 
chain might be degraded cotranslation-
ally (Figure 1B; Nottrott et al., 2006). This 
proposal is, however, based on nega-
tive rather than direct positive evidence. Cell 1For example, the identity of the putative 
protease remains unknown; and the pro-
teasome was excluded as a possibility 
because proteasome inhibitors do not 
restore protein expression from silenced 
reporters (Nottrott et al., 2006).
To investigate how miRNAs silence 
their targets, Petersen et al. (2006) 
designed a synthetic miRNA reporter 
containing a 3′ untranslated region (UTR) 
with six identical sites partially comple-
mentary to a transfected siRNA (that is, 
an miRNA mimic). When this reporter 
was transiently expressed it associated 
with polysomes, although its expres-
sion was repressed by the siRNA. But if 
translation initiation was inhibited, then 
these ribosomes dissociated more rap-
idly than those associated with a con-
trol (unrepressed) mRNA. This led to the 
suggestion that miRNAs cause prema-
ture ribosome dissociation or ribosome 
drop-off (Figure 1A).
There is additional evidence that 
miRNAs mediate repression after 
translation initiation: silencing occurs 
even when reporter mRNA translation 
is initiated by a 5′ UTR containing an 
internal ribosome entry site (IRES). 
Because IRESs initiate translation of 
mRNAs independently of the mRNA 
cap structure, these results indicate 
that miRNAs repress translation at a 
step downstream of cap recognition 
(Petersen et al., 2006).
Inhibition of Translation Initiation
In contrast to these studies, Pillai et al. 
(2005) have shown that miRNAs and 
their targets are not associated with the 32, January 11, 2008 ©2008 Elsevier Inc. 9
Figure 1. Mechanisms of miRNA-Mediated Gene Silencing
(A) Postinitiation mechanisms. MicroRNAs (miRNAs; red) repress translation of target mRNAs by blocking 
translation elongation or by promoting premature dissociation of ribosomes (ribosome drop-off). 
(B) Cotranslational protein degradation. This model proposes that translation is not inhibited, but rather 
the nascent polypeptide chain is degraded cotranslationally. The putative protease is unknown. 
(C–E) Initiation mechanisms. MicroRNAs interfere with a very early step of translation, prior to 
elongation. (C) Argonaute proteins compete with eIF4E for binding to the cap structure (cyan dot). (D) Ar-
gonaute proteins recruit eIF6, which prevents the large ribosomal subunit from joining the small subunit. 
(E) Argonaute proteins prevent the formation of the closed loop mRNA configuration by an ill-defined 
mechanism that includes deadenylation. 
(F) MicroRNA-mediated mRNA decay. MicroRNAs trigger deadenylation and subsequent decapping 
of the mRNA target. Proteins required for this process are shown including components of the major 
deadenylase complex (CAF1, CCR4, and the NOT complex), the decapping enzyme DCP2, and several 
decapping activators (dark blue circles). (Note that mRNA decay could be an independent mechanism 
of silencing, or a consequence of translational repression, irrespective of whether repression occurs at 
the initiation or postinitiation levels of translation.) RISC is shown as a minimal complex including an 
Argonaute protein (yellow) and GW182 (green). The mRNA is represented in a closed loop configuration 
achieved through interactions between the cytoplasmic poly(A) binding protein (PABPC1; bound to the 3′ 
poly(A) tail) and eIF4G (bound to the cytoplasmic cap-binding protein eIF4E).polysomal fraction in sucrose gradients 
but rather with the free mRNP pool in 
mammalian cells, indicating that trans-
lation inhibition occurs at the initiation 
step. Furthermore, in this and other 10 Cell 132, January 11, 2008 ©2008 Elseviestudies, mRNAs translated through 
cap-independent mechanisms (that 
is, through an IRES) were refractory to 
repression by miRNAs, further support-
ing the notion that miRNAs inhibit cap-r Inc.dependent translation initiation (Hum-
phreys et al., 2005; Pillai et al., 2005; 
Mathonnet et al., 2007; Wakiyama et al., 
2007).
In agreement with a role for miRNAs 
in blocking translation initiation, Kiriaki-
dou et al. (2007) reported an unexpected 
observation: the central domain of Argo-
naute proteins exhibits sequence simi-
larities to the cytoplasmic cap-binding 
protein eIF4E (eukaryotic translation 
initiation factor 4E), which is essential 
for cap-dependent translation initiation. 
eIF4E binds to the m7Gppp-cap struc-
ture of mRNAs by stacking the methy-
lated base of the cap between two 
tryptophans. At the equivalent position 
of the tryptophans in eIF4E, Argonaute 
proteins have phenylalanines that could 
mediate a similar interaction. Consis-
tently, Kiriakidou et al. (2007) showed 
that human Argonaute 2 (AGO2) binds 
to m7GTP on Sepharose beads, and that 
there is competition for this binding by a 
methylated cap analog (e.g., m7GpppG) 
but not by unmethylated GpppG. The 
authors then showed that substituting 
one or both AGO2 phenylalanines with 
valine residues abrogated the silenc-
ing activity. These results support the 
idea that miRNAs inhibit translation at 
the cap-recognition step by displacing 
eIF4E from the cap structure (Figure 1C).
Evidence suggesting that miRNAs 
inhibit an early translation step (before 
elongation) was also reported by Chen-
drimada et al. (2007). Using human cells 
they showed that AGO2 associates with 
both eIF6 and large ribosomal subunits. 
By binding to the large ribosomal sub-
unit, eIF6 prevents this subunit from pre-
maturely joining with the small ribosomal 
subunit. Thus, if AGO2 recruits eIF6, then 
the large and small ribosomal subunits 
might not be able to associate, causing 
translation to be repressed (Figure 1D; 
Chendrimada et al., 2007).
Although both Kiriakidou et al. (2007) 
and Chendrimada et al. (2007) present 
results indicating that miRNAs repress 
translation prior to the elongation 
step, they propose mutually exclusive 
underlying mechanisms. Clearly, we 
need to investigate more fully how eIF6 
and Argonaute’s putative cap-binding 
domain contribute to mRNA silencing. 
In particular, without further structural 
information on eukaryotic Argonaute 
proteins, another viable interpretation 
of Kiriakidou’s results is that mutating 
the phenylalanine residues affects the 
protein activity through an unrelated 
mechanism. Similarly, eIF6 is required 
for 60S ribosomal subunit biogenesis 
and its depletion may have second-
ary effects that we do not yet fully 
appreciate.
miRNA-Mediated mRNA Decay
Initial studies reported that animal miR-
NAs repress translation without signifi-
cantly affecting the abundance of target 
mRNAs. More recently, however, sev-
eral reports showed that animal miR-
NAs do induce significant degradation 
of target mRNAs (Bagga et al., 2005; 
Wu and Belasco, 2005; Behm-Ansmant 
et al., 2006; Giraldez et al., 2006; Wu 
et al., 2006; Chendrimada et al., 2007; 
Eulalio et al., 2007a). In agreement with 
this, the levels of predicted and vali-
dated miRNA targets increase in cells 
in which the miRNA pathway is inhib-
ited, for example, by depletion of Dicer 
or Argonaute proteins (Giraldez et al., 
2006; Rehwinkel et al., 2006; Schmit-
ter et al., 2006). Conversely, if specific 
miRNAs are ectopically expressed, 
then transcripts containing binding 
sites for those miRNAs become less 
abundant (Lim et al., 2005). Likewise, 
several examples show that express-
ing a given miRNA correlates with 
downregulation of transcripts contain-
ing complementary binding sites. For 
example, in zebrafish embryos at the 
onset of zygotic transcription, the dra-
matic increase of miR-430 expression 
correlates with the degradation of a 
large number of maternal mRNAs con-
taining miR-430 binding sites in their 3′ 
UTRs (Giraldez et al., 2006).
In animal cells, miRNAs cause decay 
of mRNAs not through endonucleolytic 
cleavage by Argonaute proteins but 
rather by directing mRNAs to the general 
mRNA degradation machinery (except 
when the miRNA is fully complementary 
to the target). This observation is sup-
ported by studies in zebrafish embryos, 
C. elegans, D. melanogaster, and human 
cells showing that miRNAs accelerate 
deadenylation and decapping of their 
targets (Behm-Ansmant et al., 2006; 
Giraldez et al., 2006; Wu et al., 2006; 
Eulalio et al., 2007a).Messenger RNA decay mediated by 
microRNAs requires Argonaute proteins, 
the P body component GW182, the 
CAF1-CCR4-NOT deadenylase com-
plex, the decapping enzyme DCP2, and 
several decapping activators including 
DCP1, Ge-1, EDC3, and RCK/p54 (Figure 
1F; Behm-Ansmant et al., 2006; Eulalio 
et al., 2007a). Current evidence indicates 
that GW182 is recruited to miRNA targets 
through direct interactions with the Argo-
naute proteins, contributing to transla-
tional repression (reviewed by Ding and 
Han, 2007; Eulalio et al., 2007b). GW182 
also marks the transcript as a target for 
decay via deadenylation and decapping 
(reviewed by Ding and Han, 2007; Eulalio 
et al., 2007b).
Although compelling evidence shows 
that miRNAs trigger degradation of their 
targets, a critical question remains open: 
Is degradation an independent mecha-
nism by which silencing is accomplished, 
or is it a consequence of a primary effect 
on translation? Some evidence suggests 
that miRNA-mediated mRNA decay can 
be uncoupled from translation. In human 
cells, an miRNA target whose translation 
was inhibited by inserting a strong stem 
loop structure in its 5′ UTR was never-
theless deadenylated in an miRNA-de-
pendent manner (Wu et al., 2006). Like-
wise, in zebrafish embryos and human 
cell extracts, miRNA targets were dead-
enylated despite having a defective cap 
structure (Appp-cap) that impairs trans-
lation (Mishima et al., 2006; Wakiyama 
et al., 2007). Furthermore, in D. mela-
nogaster cells and human cell extracts, 
miRNA-mediated mRNA decay could 
occur in the absence of active transla-
tion (Eulalio et al., 2007a; Wakiyama et 
al., 2007).
The extent of degradation is clearly 
specified by the mRNA target and not 
by the miRNA itself because the same 
miRNA can either repress translation or 
induce mRNA decay in a target-specific 
manner (Eulalio et al., 2007a). Alemán 
et al. (2007) found that whether miRNA 
mimics elicit decay or translational 
repression depends on the structure 
of the miRNA-mRNA duplexes (that is, 
the number, type, and position of mis-
matches). Grimson et al. (2007) found 
that the number of miRNA binding sites, 
the distance separating these sites, 
their position within the 3′ UTR, and Cell 13the RNA context strongly influence the 
magnitude of the regulation, although 
the relative contributions of translational 
repression and decay in each case 
were not established. Thus, whether or 
not miRNAs elicit mRNA degradation 
strongly depends on specific features 
of the miRNA-binding site and its RNA 
context and so, most likely, on the spe-
cific complement of proteins associated 
with a given target.
Sequestration in P Bodies
Argonaute proteins, miRNAs, and miRNA 
targets colocalize to cytoplasmic foci 
known as P bodies. Additional compo-
nents of P bodies include GW182, the 
CAF1-CCR4-NOT deadenylase complex, 
the decapping enzyme DCP2, decapping 
activators (e.g., DCP1, EDC3, Ge-1), and 
the RNA helicase RCK/p54, all of which 
have been implicated in miRNA function 
(reviewed by Eulalio et al., 2007b; Parker 
and Sheth, 2007).
The detection of Argonaute proteins, 
miRNAs, and miRNA targets in P bodies 
led to a model in which miRNA targets get 
sequestered in P bodies, where they are 
shielded from the translation machinery 
and may undergo decay (Eulalio et al., 
2007b; Parker and Sheth, 2007). It has 
been debated whether the localization to 
P bodies is a cause or a consequence 
of silencing. However, recent stud-
ies demonstrate that the miRNA path-
way remains unaffected in cells lacking 
detectable microscopic P bodies (Chu 
and Rana, 2006; Eulalio et al., 2007c). 
Thus, although P body components play 
crucial roles in miRNA-mediated silenc-
ing, aggregation into microscopic P bod-
ies is not required for miRNA function. 
These results imply that silencing is initi-
ated in the soluble cytoplasmic fraction, 
and that the localization of the silencing 
machinery in P bodies is a consequence 
rather than a cause of silencing (Hum-
phreys et al., 2005; Pillai et al., 2005; Chu 
and Rana, 2006; Eulalio et al., 2007c).
Insights from In Vitro Studies
The inhibition of translation initiation 
by miRNAs has been recapitulated in 
vitro, in cell-free extracts of diverse ori-
gin. These include rabbit reticulocyte 
lysates (Wang et al., 2006), D. melano-
gaster embryo extracts (Thermann and 
Hentze, 2007), and extracts from two 2, January 11, 2008 ©2008 Elsevier Inc. 11
different mammalian cell lines, mouse 
Krebs-2 ascites, and human HEK293F 
cells (Mathonnet et al., 2007; Wakiyama 
et al., 2007). In these extracts, miRNAs 
silenced translation of m7Gppp-capped 
mRNAs but not of transcripts carrying an 
artificial Appp-cap structure (irrespec-
tive of the poly(A) tail). In mouse and 
human cell extracts, transcripts initiating 
translation in an IRES-dependent man-
ner (thus cap-independent) were refrac-
tory to miRNA regulation (Mathonnet et 
al., 2007; Wakiyama et al., 2007).
Few studies have investigated the 
poly(A) tail’s role in silencing; but when 
this issue was addressed explicitly, 
nonpolyadenylated mRNAs were either 
silenced in vivo (Pillai et al., 2005; Wu et 
al., 2006) or were partially or fully refrac-
tory to silencing in vivo and in vitro, 
respectively, regardless of the cap struc-
ture (Humphreys et al., 2005; Wang et al., 
2006; Wakiyama et al., 2007).
Wakiyama et al. (2007) observed a 
strict requirement for both the cap struc-
ture and the poly(A) tail for silencing. 
Moreover, their extracts recapitulated 
miRNA-mediated deadenylation as pre-
viously observed in zebrafish embryos 
and in human and D. melanogaster cells 
(Behm-Ansmant et al., 2006; Giraldez et 
al., 2006; Wu et al., 2006). Based on these 
observations, Wakiyama et al. (2007) 
proposed that miRNAs trigger dead-
enylation; consequently in this model, 
translation is repressed because the cap 
structure and the poly(A) tail cannot syn-
ergize (Figure 1E). It is well established 
that if the cytoplasmic poly(A)-binding 
protein (PABPC1) is bound to an mRNA 
poly(A) tail, it can interact with transla-
tion initiation factor 4G (eIF4G); eIF4G 
is bound to the cap structure through 
interactions with eIF4E. This interaction 
induces mRNA to form a closed loop 
(Figure 1B), which greatly enhances 
translation (see Wakiyama et al., 2007 
and references therein). Silenced mRNAs 
will not form a closed loop because they 
are deadenylated.
Notably, there is also debate about 
whether deadenylation is the cause or 
the consequence of silencing. Wakiyama 
et al. (2007) found that all mRNAs con-
taining miRNA-binding sites were deade-
nylated in an miRNA-dependent manner, 
including those refractory to silencing 
because of the presence of an Appp-cap 12 Cell 132, January 11, 2008 ©2008 Elsevieor an IRES in their 5′ UTR; this finding is 
in agreement with results reported in 
zebrafish embryos (Mishima et al., 2006). 
Deadenylation also occurred in the pres-
ence of cycloheximide, suggesting that 
it does not require ongoing translation. 
These results were interpreted as evi-
dence that deadenylation causes the 
translational repression (Wakiyama et 
al., 2007).
Other studies suggest that beyond 
deadenylation, additional mechanisms 
cause translational repression. For exam-
ple, depleting an essential component of 
the deadenylase complex (that is, NOT1) in 
D. melanogaster cells prevented miRNA-
mediated mRNA decay; however, protein 
expression was not fully restored indicating 
that the reporters remained silenced at the 
translational level (Behm-Ansmant et al., 
2006). Similarly, Wu et al. (2006) showed 
that, in human cells, a reporter mRNA in 
which the poly(A) tail was replaced by a 
histone-stem loop structure was never-
theless repressed by an miRNA, demon-
strating that translational repression is not 
caused by deadenylation.
A striking finding has been reported by 
Mathonnet et al. (2007): adding purified 
initiation complex eIF4F (which includes 
the cytoplasmic cap-binding protein 
eIF4E, the scaffolding protein eIF4G, and 
the RNA helicase eIF4A) counteracted 
silencing. This fits nicely with the idea 
that the Argonaute proteins compete with 
eIF4E for binding to the cap structure as 
proposed by Kiriakidou et al. (2007). The 
displacement of eIF4E would prevent the 
circularization of the mRNA and conse-
quently enhance deadenylation. In sum-
mary, although the in vitro studies differ 
in the details, they all point to a role for 
miRNAs in interfering with early steps of 
translation initiation.
Why So Many Mechanisms?
It is hard to reconcile the different 
reported modes of miRNA regulation 
of gene expression. Perhaps these dif-
ferent modes reflect different interpre-
tations and experimental approaches. 
Another possibility is that miRNAs do 
indeed silence gene expression via mul-
tiple mechanisms. Finally, miRNAs might 
silence gene expression by a common 
and unique mechanism; and the multiple 
modes of action represent secondary 
effects of this primary event.r Inc.Are We Measuring What Matters in 
Silencing?
In principle, it should be easy to dis-
criminate the post-initiation mode from 
the initiation mode of miRNA-mediated 
repression by analyzing the position of 
the silenced mRNA reporter in sucrose 
sedimentation gradients. In the first case, 
the reporter is expected to cofractionate 
with polysomes, whereas in the second 
case it should be present in the free RNP 
fraction (that is, at the top of the gradi-
ent). Unfortunately, these experiments 
do not give clear-cut results and their 
interpretation has proven problematic.
First, except for EDTA treatments, 
most conditions that disrupt polysomes 
(e.g., puromycin, hippuristanol, or pac-
tamycin treatments) do not quantita-
tively shift mRNAs from the polysome 
fraction to the free mRNP fraction but 
rather from heavy to lighter fractions of 
the gradient. This shift could be, in some 
cases, within experimental variations of 
the measurements. Second, inhibitory 
effects of miRNAs are in the 2- to 5-fold 
range. Hence, 50%–20% of the reporter 
mRNA is not silenced. This heteroge-
neity of the reporter mRNA population 
likely obscures the results. Third, a frac-
tion of repressed mRNA may be partially 
degraded (most studies cannot rule out 
10%–15% degradation of the reporter); 
depending on the degree of regulation, 
this may represent a significant fraction 
of the silenced mRNA.
Given the difficulties mentioned above, 
it is not surprising that sedimentation 
profiles do not provide incontrovertible 
evidence for or against a specific mech-
anism. Aware of the limitations of this 
approach, many studies have validated 
their conclusions using an independent 
strategy. The use of IRES represents 
such an independent approach. The 
results obtained with IRES-containing 
reporters have been consistent with the 
analysis of polysome profiles within a 
given study but have been surprisingly 
inconsistent between different studies, 
suggesting an experimental bias.
An Experimental Approach Bias?
Most evidence that translation ini-
tiation is inhibited comes from stud-
ies of mRNAs synthesized in vitro 
and incubated in cell-free extracts or 
transfected into cultured cells. In vivo, 
miRNA targets are not “naked” mRNAs 
but exist as ribonucleoprotein particles 
or mRNPs. It is generally accepted 
that RNA-binding proteins are depos-
ited on mRNAs cotranscriptionally 
or during processing. Therefore, the 
full complement of proteins associat-
ing with mRNAs transcribed in vivo is 
likely to be different from that bound 
to the same mRNA in an in vitro sys-
tem or following mRNA transfection. 
This may explain some discrepancies 
observed, for example, between stud-
ies by Humphreys et al. (2005) on the 
one hand and Petersen et al. (2006) on 
the other. The implication is that RNA-
binding proteins strongly influence the 
final outcome of miRNA regulation.
Another potential source of discrep-
ancy is the nature of the reporter. Some 
studies used artificial reporters contain-
ing multiple identical miRNA-binding 
sites inserted in a heterologous 3′ UTR. 
These artificial reporters require up to 
six binding sites for efficient silencing, 
whereas natural 3′ UTRs seldom have 
six identical, regularly spaced binding 
sites for the same miRNA. Thus, it is 
possible that the artificial reporters do 
not fully recapitulate miRNA regulation. 
Yet, when such reporters were used, dif-
ferent mechanisms could be observed; 
so these reporters alone do not explain 
all of the discrepancies (Humphreys et 
al., 2005; Petersen et al., 2006; Waki-
yama et al., 2007).
Additional experimental differences 
reside in the use of in vivo transcribed 
and processed miRNAs versus trans-
fected siRNAs. Transfected siRNAs 
are believed to act as miRNAs, pro-
vided that the reporter contains par-
tially complementary binding sites. In 
human cells, however, it is not clear how 
the biogenesis pathway or the struc-
ture of the double-stranded miRNA or 
siRNA intermediate influences which 
Argonaute protein they associate with. 
However, studies in D. melanogaster 
demonstrated that it is the structure 
of the small RNA duplex rather than 
the biogenesis pathway that specifies 
which Argonaute-containing complex is 
loaded with the miRNA or siRNA (Tomari 
et al., 2007). If this were the case also in 
human cells, endogenous miRNAs and 
transfected siRNAs could end up in dif-
ferent Argonaute complexes.There are four human Argonaute 
paralogs; all are presumed to repress 
translation through a similar mechanism 
(although this was never investigated in 
great detail). Moreover, most studies did 
not establish which human Argonaute 
paralog was responsible for the silencing 
activity. This raises the following ques-
tion: Do different Argonaute proteins 
silence partially complementary targets 
through similar or different molecular 
mechanisms? The corollary is whether 
discrepancies between different studies 
reflect the action of different Argonaute 
proteins or Argonaute complexes with 
distinct protein compositions. Indeed, 
biochemical purification of Argonaute-
containing mRNA-protein complexes 
reveals partially nonoverlapping sets of 
mRNAs in association with individual 
Argonaute proteins, suggesting some 
degree of specificity in target selection 
(Beitzinger et al., 2007).
Multiple Mechanisms or Multiple 
Outputs?
Studies comparing natural full-length 3′ 
UTRs suggest that the final outcome of 
miRNA regulation depends on the fea-
tures and sequence of the target’s 3′ 
UTR (Behm-Ansmant et al., 2006; Eula-
lio et al., 2007a; Grimson et al., 2007). In 
these studies, the contribution of trans-
lational repression or mRNA degrada-
tion to gene silencing differed for each 
miRNA target pair.
Stress conditions provide additional 
evidence that the context of the 3′ UTR is 
important, as binding of a protein known 
as HuR to the 3′ UTR of cationic amino 
acid transporter 1 (CAT-1) mRNA relieves 
miR-122-mediated silencing. Although it 
remains to be determined whether HuR 
directly displaces miR-122 or interferes 
indirectly with its function in cis, it seems 
likely that other RNA-binding proteins 
might also counteract, modulate, or influ-
ence the extent and mode of miRNA reg-
ulation in a target-specific manner. This 
is supported by the increasing number of 
examples in which RNA-binding proteins 
modulate miRNA function (reviewed by 
Leung and Sharp, 2007).
Nevertheless, it is still possible that 
miRNAs silence gene expression through 
a common and unique mechanism, and 
that the multiple modes of action reflect 
secondary consequences of this primary Cell 13event rather than independent mecha-
nisms. These secondary effects will vary 
in a cell- or target-dependent manner. 
For instance, translational repression 
may represent a primary event that in a 
target- or cell-specific manner may or 
may not lead to mRNA decay. Indeed, 
proteins bound to the target mRNA may 
influence degradation. Cell-specific 
effects are also possible: for example, 
zebrafish nanos1 mRNA is deadenylated 
and degraded by miR-430 in somatic 
cells yet is refractory to miR-430 regu-
lation in the germline (Mishima et al., 
2006).
Likewise, one could envisage cotrans-
lational protein degradation as a conse-
quence of a primary event that occurred 
during translation elongation; the silenced 
ribosome signals aberrant translation 
such that the nascent polypeptide chain 
is degraded. Examples showing nascent 
polypeptides being cotranslationally 
degraded have been described (Nottrott 
et al., 2006 and references therein).
Conclusion
A growing body of evidence indicates 
that miRNAs play important roles in 
the pathogenesis of human diseases 
such as cancer, neurodegenerative and 
metabolic disorders, and viral infection. 
A detailed mechanistic understanding 
of miRNA-mediated gene regulation is 
therefore of critical importance to evalu-
ate the potential of miRNAs as thera-
peutic targets. Although we have begun 
to understand miRNA biogenesis and 
have identified key effectors of miRNA 
function, the mechanisms of action of 
miRNAs in animal cells are still being 
hotly debated. We consider it unlikely, 
though, that the diverse mechanisms 
observed result from different techni-
cal approaches. Rather, we favor a view 
whereby miRNA repression is mani-
fested in distinct ways depending upon 
the specific features and composition 
of the mRNP target. Currently, we can-
not determine whether these different 
modes of repression represent multiple 
independent silencing mechanisms or 
multiple outputs from a unique primary 
inhibitory event.
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